In pharmaceutical innovations, voretigene neparvovec is only accessible for a small percentage of RP patients with the particular RPE65 mutation; there is no viable curative treatment for the vast majority of RP patients, with significant unmet demand. Here, RPE65 is linked to retinitis pigmentosa 1.